Research programme: cyclophilin inhibitors - NeuroVive

Drug Profile

Research programme: cyclophilin inhibitors - NeuroVive

Alternative Names: BC 556; nPT-CyP; NV 556; NVP 018; NVP 024; NVP 025; NVP-022; NVP018/BC556; OCB-030; Sangamides

Latest Information Update: 09 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotica Technology
  • Developer Arbutus Biopharma; Karolinska Institute; NeuroVive Pharmaceutical
  • Class Macrolides
  • Mechanism of Action Cyclophilin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Non-alcoholic steatohepatitis

Highest Development Phases

  • Preclinical Hepatocellular carcinoma; Non-alcoholic steatohepatitis
  • Research Mitochondrial myopathies
  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 18 May 2017 NeuroVive Pharmaceuticals and Karolinska University Hospital enter a research collaboration to develop NVP 025 for Mitochondrial myopathy
  • 22 Feb 2017 NeuroVive enters into a research collaboration with The Scripps Research Institute to explore the mechanisms of action of sanglifehrin-based cyclophilin inhibitors
  • 22 Feb 2017 NeuroVive Pharmaceutical in-licenses Engitix' human liver 3D models technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top